Sofosbuvir and ribavirin use in wait‐listed patients with hepatitis C should be selective

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|1|7-8

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.1, 2015-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1793-1797

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1–infected patients

By  

HEPATOLOGY, Vol. 61, Iss. 3, 2015-03 ,pp. : 790-801

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

By  

HEPATOLOGY, Vol. 61, Iss. 3, 2015-03 ,pp. : 769-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite